FDA Approval of Lenacapavir: A Significant Step Forward in HIV Prevention
Wednesday, 18 June 2025, 20:31
FDA Approval of Lenacapavir: A Major Leap in HIV Prevention
The U.S. Food and Drug Administration (FDA) has officially approved lenacapavir as a twice-yearly injection for preventing HIV. The drug, marketed as Yeztugo by Gilead Sciences, was approved after clinical trials demonstrated that 99.9% of participants maintained a negative HIV status.
Impact of Lenacapavir's Approval
- Significant Reduction in HIV Cases
- New Hope for Higher Risk Populations
- Clinical Trials Show High Effectiveness
According to Daniel O'Day, Gilead’s chairman and CEO, this FDA approval is a pivotal moment in HIV prevention, heralding a new era in treatment options.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.